EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits https://t.co/KUB7fpmdbf

Exercise Can Improve Pain A pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P<0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and https://t.co/rbZlyfrCOW

Study of 64 Stills related #MAS pts (55 sJIA; 9 AOSD). All Rx GCs; 75% anakinra, 52% ciclosporin. Complete remission in 7, partial Rem in 64%; GCs tapered in 78% in median 40d. MAS recurred in 31%; 11% died; 1-year survival probability 93.75% https://t.co/HxhhpRsSMO https://t.co/IQHLRlULcP

Retrospective real world avacopan (AVCP) safety data from UK vasculitis center looked at AAV pts (RTX or CTX) rx w/ AVCP (n 133) or not AVCP (n 458). @1 yr AVCP had nonsignif incr in ALT >2xULN (15.8% v 11.4%) or >3xULN (11.3% v 6.3%; P 0.064) No diff in Alk phos, Bili, Hy's law https://t.co/ZZhpxdKhQl

43 biopsy-proven Giant cell arteritis in Black Caribbeans - GCA incidence rate 1.76/100K pY (1/2 rate of whites) w/ 4 fold incr betw 1993 & 2014. Mean Age 76; F:M ratio 4.4. Initial Sxs HA (65%), jaw claud (33%), scalp tender (37%), anterior ischemic optic neuropathy (26%) & PMR https://t.co/lHAeNdOqbj

Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less https://t.co/18DM2UL6vB

UK longitudinal study 46 adult PsA pts w/ BMI ≥25 showed use of digital wt. & Dz app (vs no app) improved weight loss (− 1.55 vs − 0.18 kg), dz activity by CPDAI (p < 0.001), esp w/ arthritis (p 0.017) & enthesitis (p  0.034) domains. Weight loss correlated w/ dz activity https://t.co/Y9zVyPmsNl

T-cell engager blinatumomab (CD3xCD19 TCE) was used for Deep B-cell depletion in 15 resistant RA pts (MDR-RA). @wk 12 9/15 CDAI LDA, 3/15 CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. Later, 14/15 flared. No ICANs, 3/15 w/ CRS (gr 1) https://t.co/ddLb7lIHka

Metanalysis of IVIG in scleroderma (11 studies, 363 pts) showed IVIG to be safe; signif improvement in skin by mRSS (SMD −0.59; p 0.0019) & GI Dz (SMD −0.73; p 0.0012; I2 = 0%). W/ inflam myopathy signif reduction in CK (SMD −0.53; p<0.001) https://t.co/h53FrACCgA https://t.co/qavoD3Vren

Biogen announced the 52 week OL results of AMETHYST Phase 2/3 RCT of litifilimab in 93 #CLE pts. Betw wk 24 & 52, pts improved w/ clear skin (27.2%; CLA IGA 0-1) & 29% CLASI-70 (dz activity) https://t.co/61zxVhUwuj https://t.co/9oGXGcom2m

2 cohorts of GC naive, suspected (n 185) PMR pts studied with MSK ultrasound - 67% Dx w/ PMR clinically. No single MSK US finding was ound pathognomonic for PMR. Best specificity (85-93%) was 1+ inflammatory lesion in both the shoulder & hip girdles https://t.co/XOXGeTBl5m https://t.co/3GADGo73l1

Using national survey data of adults (62-85 yrs) saw no change in Rx Med (84% vs 85%) or dietary supplement (66% vs 67%) use betw 2015-2016 & 2021-2013. But OTC declined (60% vs 55%; P = .04). Polypharmacy signif incr. Drug-drug interactions declined (26% vs 22%; P .02) w/ https://t.co/16xPyKS2aU

Ambient AI in Rheumatology Practice: Less Typing or Less Human? Rheumatology has become a sedentary, computer-based job. We sit at our computers to pre-chart, type during patient visits, and bring notes home to finish on laptops while sitting on the couch. Do you spend more https://t.co/zr56f7iCrJ

Danish national study (2003-2024) of 51,401 #PMR pts (24K PCPs, 27K secondary MDs): PMR incidence = 112/100K. PMR decr 53% in primary care & incr 30% in secondary care (overall 12% decline). Among PMR, GCA rate was 5.4/1,000 PYs, w/ median 68 days from PMR Dx. 28% & 22% were https://t.co/1VlI5r1r0L

Multicenter retrosp study 2865 #RA pts (dz duration 2 yrs) starting b/tsDMARDs (TNFi, IL-6i, RTX, ABA, JAKi) - 50% were on steroids (GC). At 3 & 6 mos, only 26% & 37% D/C GC. GC D/C more w/ JAKi (24 v 17%). Predictors on NON-D/C: Chronic GC, HTN, TNFi, RTX, ABA (vs JAKi) https://t.co/JSve6M9hwm